HUTCHMED’s Post

Alligator Bioscience AB has announced positive 18-month follow-up data from the OPTIMIZE-1 Phase 2 study of the company’s lead asset mitazalimab in 1st line metastatic pancreatic cancer. The open-label, multi-center study assessed the safety and efficacy of anti-CD40 mitazalimab in combination with standard of care chemotherapy mFOLFIRINOX, in previously untreated, chemotherapy naïve pancreatic cancer patients. The data demonstrated 18-month survival rate of 36.2% in patients treated with mitazalimab in combination with mFOLFIRINOX, compared to 18.6% reported with FOLFIRINOX alone. Alligator is continuing its preparations for the global Phase 3 registration study to evaluate mitazalimab in pancreatic cancer and the company remains on track to initiate the study in 2025.  https://lnkd.in/dVgcV5Fr

We are pleased to share the results from our preclinical studies demonstrating that our drug #bisantrene, when used in combination with another cancer drug #decitabine, offers significantly improved cancer cell-killing across a broad panel of 143 tumour cell lines. Notably, the combination of these drugs is much more effective than either compound taken on its own. CEO Dr Daniel Tillett comments: “These results open exciting new treatment opportunities for both bisantrene and decitabine. While decitabine has proven its effectiveness in haematological cancers, it has not demonstrated clinical utility in solid tumours, like lung or breast cancer. This new body of work is highly supportive of the results from the University of Newcastle in preclinical AML models using a combination of bisantrene and decitabine. Thanks to the continued support of our shareholders, we are looking forward to announcing a clinical trial of this promising anticancer drug combination in the near future.”   More details here: https://lnkd.in/gsEKzZK6 #CancerTreatment #KillCancer

🔦 Saturday Spotlight 🔦 Today we’re highlighting PanTher Therapeutics! PanTher Therapeutics is on a mission to redefine cancer treatment with therapeutics designed to act precisely at the tumor site for enhanced clinical outcomes and minimal side effects. While there have been tremendous advances in cancer treatment, critical challenges remain including limited ability of drugs to successfully reach the tumor, short half-life, and low retention rate on site. PanTher has reimagined cancer therapies to tackle these long-standing challenges to successful treatment of the deadliest cancers. With its Sagittari™ platform, PanTher has engineered form factors that enable the direct targeting of drugs and other therapeutics precisely to the tumoral area. Watch Laura Indolfi’s full presentation from #LSIEurope23 to learn more about PanTher Therapeutics: https://lnkd.in/gK28UiRG

Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan This approval to proceed with the Phase 2 clinical trials in Japan and Taiwan are expected to accelerate the collection of patient and response data needed for the next-stage of evaluation and development of LP-300, a therapeutic for the treatment of relapsed and inoperable primary adenocarcinoma of the lung given in combination with chemotherapy  Additionally, it  may also bring a needed therapeutic option for LCINS diagnosed patients in Japan and Taiwan, where one-third of all lung cancer diagnoses are made among those who have never smoked.

📢Exciting breakthrough in NSCLC treatment as Summit Therapeutics, Inc. has just announced some game-changing results from the HARMONi-2 trial for their bispecific antibody, Ivonescimab, in treating non-small cell lung cancer (NSCLC). The Phase III trial revealed that Ivonescimab monotherapy significantly outperforms the current standard, Pembrolizumab, showing great promise for patients with locally advanced or metastatic NSCLC 🚀 The trial demonstrated a statistically significant improvement in progression-free survival (PFS) with Ivonescimab across various patient subgroups, including those with varying levels of PD-L1 expression. This is a monumental step forward in oncology, especially for those at high risk or with different histologies. The detailed results will be showcased at the upcoming World Conference on Lung Cancer (WCLC 2024) 📊 #SummitTherapeutics #HealthcareInnovation #OncologyResearch #ClinicalResearch #ClinicalTrials #Oncology #NSCLC #WCLC2024 #LifeScience #ElixirAssociates #StaffingPartner

At this year’s CHI Summit, Kirsty Crame - van Nierop presented a comprehensive overview of the Company's lead candidate MDG1015 highlighting its technologies to enhance T cell receptor engineered T cell (TCR-T) therapies. MDG1015, a first-in-class, third generation TCR-T therapy, is derived from Medigenes End-to-End Platform and #IND-ready. It targets the tumor-specific cancer testis antigen NY-ESO-1/LAGE-1a and is armored and enhanced with the proprietary PD1-41BB costimulatory switch protein. Subject to financing, a first-in-human trial for MDG1015 is planned for gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma with IND/CTA filing targeted for 2H 2024. Read here the full PR: https://lnkd.in/dZvU7kyN Find more details on Medigene AG End-to-End Platform here: https://lnkd.in/eDjmquVJ

Join this week's Cholangiocarcinoma Foundation Educational Webinar: A clinical trial for a potential new tHER2apy for biliary tract cancers with James J Harding, MD, with Memorial Sloan Kettering Cancer Center and Phillip Garfin, MD, PhD from Jazz Pharmaceuticals. This presentation will cover the Human Epidermal Growth Factor Receptor-2 (HER2) protein and its role in cancer, with a focus on biliary tract cancers. Presentation Highlights: 🗣 Discussion on designing cancer treatments targeting HER2 💊 Introduction to Zanidatamab as a potential treatment for HER2-positive cancers 📊 Insights from a recent clinical study on the safety and efficacy of Zanidatamab in BTC treatment Register here: https://lnkd.in/gEEdN-64

We are happy announce that during the 46th San Antonio Breast Cancer Symposium (#SABCS 2023), a first-in-human clinical trial on SIM0270, a brain-penetrating selective estrogen receptor degrader (SERD) molecule independently developed by Simcere Zaiming, was presented at the POSTER SPOTLIGHT session as mini oral presentation. The preliminary findings have shown good tolerability and anti-tumor activity in patients with advanced or metastatic ER+/HER2- who have undergone multiple lines of treatment.   At the same time, a pos hoc analysis of COSELA (trilaciclib), an innovative reversible CDK4/6 inhibitor co-developed by G1 Therapeutics, Inc. and Simcere was also published at 2023 SABCS poster session, revealing long-term survival benefits to patients with metastatic triple-negative breast cancer in the phase II clinical trial. 

I previously shared that Daiichi Sankyo will present new clinical research across its DXd antibody drug conjugate (ADC) portfolio during the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer. The immense potential of the Daiichi Sankyo, Inc. pipeline is enabling the organization to expand research across a variety of different tumor types. There was one session during #WCLC23 that uniquely represented the promise and potential of our DXd ADC strategy called “Antibody Drug Conjugates: The Next Tsunami.” This was the first time ever where three Daiichi Sankyo ADCs were featured together in one session with new data from our HERTHENA-Lung01 and TROPION-Lung04 trials along with a subgroup analysis of a phase 1/2 study. ADCs are already changing the standard of care and the prognosis for patients and sessions like this continue to explore and demonstrate the potential of these medicines for patients. #oncologyresearch

Advancements in the Genitourinary Cancer Market! ASCO 2024 conference is poised to unveil groundbreaking advancements in the realm of genitourinary cancers, focusing on prostate cancer, bladder/urothelial cancer, and renal cell carcinoma. Leading pharmaceutical giants like Novartis, Pfizer, Merck, Arvinas, Astellas Pharma, Janssen Inc., Orion Pharma Ltd, and others are gearing up to present their latest research and developments, sparking significant interest and discussions throughout the event. A major highlight of ASCO 2024 will be CG Oncology's final results from the CORE-001 Phase II trial of cretostimogene in combination with KEYTRUDA. These findings are anticipated to signal a potential paradigm shift in the treatment landscape for NMIBC, offering newfound hope for patients unresponsive to traditional BCG therapy. To get exclusive insights on the genitourinary cancer treatment market, visit: https://lnkd.in/gnwgiqqt #ASCO2024 #GenitourinaryCancers #ProstateCancer #BladderCancer #RenalCellCarcinoma #PharmaResearch #Novartis #Pfizer #Merck #Arvinas #AstellasPharma #Janssen #OrionPharma #MedicalInnovations #CancerTreatment #ClinicalTrials #NMIBC #BCGTherapy #CancerResearch #HopeForPatients